Drainage device implantation riskier than trabeculectomy

Article

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

Frank A. Sloan, PhD of the Center for Health Policy, Duke University, North Carolina, US and colleagues conducted a retrospective, longitudinal cohort analysis of subjects (aged ≥68 years) undergoing PT, TS or GDD implantation between 1994–2003, with follow-up to 2005, to determine rates of postoperative adverse outcomes.

Retinal detachment, endophthalmitis and suprachoroidal haemorrhage were classified as severe complications; choroidal detachment, corneal oedema and hypotony were classified as less serious outcomes.

At the one year follow-up point, severe adverse events in the GDD implantation, TS and PT subject groups were 2.0%, 1.3% and 0.6%, respectively; rates of subjects developing less serious adverse events and low vision/blindness were higher in the GDD group than in the TS and PT groups. After controlling for demographic factors, differences were reduced but not to a statistically significant degree.

Regardless of controlling for demographic factors, the rates of adverse events across the spectrum of severity were slightly higher for patients undergoing GDD implantation than TS or PT surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.